NCT00110721 - GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

February 29, 2008

Conditions

Colorectal Cancer

Interventions

DRUG

GM-CT-01 plus 5-Fluorouracil

Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.

Trial Locations (6)

34952

Hematology-Oncology Associates of the Treasure Coast, Port Saint Lucie

70121

Ochsner Clinic Foundation, New Orleans

84101

Soroka University Medical Center, Beersheba

91031

Shaare Zedek Medical Center, Oncology, Jerusalem

06708

Medical Oncology and Hematology, Waterbury

Unknown

University of Michigan Comprehensive Cancer Center, Ann Arbor